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This is anOpAbstract – In Canada, ∼17millions of adults between 30–64 years old could beneﬁt from a prevention
strategy to lower the risk of Alzheimer’s disease (AD). My group is working on a population that is
particularly at risk of AD, the carriers of an epsilon 4 allele of apolipoprotein E (E4), a genetic risk. Around
20% of the population in industrial countries have this genetic risk but not all carriers will develop AD,
suggesting that environmental factors modulate the clinical manifestation and risk of AD in the carriers. My
group has discovered that the metabolism of docosahexaenoic acid (DHA) is disrupted during aging and in
E4 carriers, a ﬁnding replicated in homozygous mice knocked-in for human E4 allele (hAPOE4). We
recently showed that a diet containing DHA prevented behavioral deﬁcits in hAPOE4 mice. Another group
reported in E4 carriers that the ratio of arachidonic acid (ARA): DHA is disrupted in the plasma and
constitute a preclinical marker of mild cognitive impairment/AD in E4 carriers. Using our kinetics
approaches with uniformly labelled carbon 13 fatty acids, we showed that the kinetics of 13C-DHA is
modiﬁed by age and E4 carriage. The kinetics of 13C-arachidonic acid was however not modiﬁed by age
conversely to that of 13C-eicosapentaenoic acid (EPA).We also reported that the synthesis of 13C-DHA from
13C-EPA started 2 h after the tracer intake in older adults conversely to 7 d in young men. Whether old men
needs in DHA is higher or whether their ability to use it is lower remains to be established. These differences
in the DHA and EPA metabolism seems, however related to physiological modiﬁcations occurring during
aging and in E4 carriers and obscure the relationship between plasma DHA and EPA levels, dietary fatty ﬁsh
intake and cognitive status.
Keywords: docosahexaenoic acid / arachidonic acid / eicosapentaenoic acid / aging / cognitive decline /
apolipoprotein E / kinetics
Résumé – Vieillissement, déclin cognitif, apolipoprotéineE et métabolisme de l’acide docosahexa-
énoïque.Au Canada, 17millions d’adultes âgés entre 30–64 ans pourraient bénéﬁcier d’une intervention en
prévention pour diminuer leur risque de développer la maladie d’Alzheimer (MA). L’un des groupes les plus
à risque de développer la MA, les porteurs de l’allèle epsilon 4 de l’apolipoprotéine E (E4), est au centre des
recherches menées par mon groupe. Environ 20% de la population des pays industrialisés sont porteurs d’E4
mais ce ne sont pas tous les porteurs qui développeront la MA, ce qui suggère que des facteurs
environnementaux puissent moduler l’expression clinique et le risque de la MA chez les porteurs. Nous
avons découvert que le métabolisme de l’acide docosahexaénoïque (DHA) est débalancé pendant le
vieillissement et chez les porteurs de l’E4. Ces découvertes ont été répliquées dans un modèle de souris
transgénique dont l’apolipoprotein de souris a été remplacé par de l’E4 humaine (hAPOE4). Nous avons
récemment montré qu’une diète riche en DHA prévenait les déﬁcits comportementaux chez la souris
hAPOE4. Un autre groupe a montré que le ratio acide arachidonique (ARA) : DHA était débalancé dans le
plasma des humains E4 et que ce marqueur constituait un marqueur pré-clinique de déclin cognitif léger/MA
chez les E4. Avec notre approche de cinétique des acides gras uniformément marqués au carbone 13, nous
avons montré que les cinétiques du 13C-DHA et du 13C-eicosapentaénoïque (EPA) étaient modiﬁées avec
l’âge et chez les porteurs de l’E4. Cependant, la cinétique du 13C-ARA n’était pas modiﬁée avec l’âge. Nousdence: Melanie.Plourde2@usherbrooke.ca
en Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
M. Plourde: OCL 2018, 25(4), D405avons également rapporté que, chez les personnes âgées, la synthèse du 13C-DHA débutait 2 h après la
consommation du 13C-EPA tandis que cette production débutait seulement 7 jours après sa consommation
chez les participants jeunes. Il est donc important de comprendre si les besoins en DHA des personnes âgées
sont plus importants que ceux des jeunes, d’où sa synthèse précoce à partir de l’EPA ou si l’habilité des
participants âgés à utiliser le DHA est plus basse, ce qui expliquerait son accumulation dans le plasma. Ces
différences dans le métabolisme de l’EPA et du DHA semblent reliées à des modiﬁcations physiologiques
qui ont lieu durant le vieillissement et chez les porteurs de l’E4, ce qui pourrait obscurcir la relation entre
leurs niveaux dans le sang, la consommation de poisson gras et le statut de la cognition.
Mots clés : acide docosahexaénoïque / acide arachidonique / acide eicosapentaénoïque / vieillissement / déclin
cognitif / apolipoprotéine E / cinétique1 Introduction
In Canada, 5.5million (16% of Canadians) of adults are
> 65 years old and projections suggest this number will be
around 20% of Canadians by 2024. In France in 2005, 16% of
French were > 65 years old representing around 10.7million
citizen. Projection scenario points towards > 25% of French
being> 65 in 2030 in this represents roughly 17million people.
With higher life expectancy, older adults will live longer with a
chronic disease. Among chronic diseases, Alzheimer disease
(AD) is the one disease older adults is the most afraid of because
the disease lead to memory decline and subsequently to lower
ability to takecareof themselves.TheAlzheimerSocietyCanada
reports that the current number of Canadians living with a
cognitive disease is 564 000 and that there are each year
25 000 new cases. In the next 15 years, it is anticipated that the
number of Canadian affected by a cognitive disease will double.
The annual cost to Canadian to take care of someone with a
cognitive disease is> $10 billionCANannually. The scenario is
similar in France and in other industrial countries.
AD is characterized by memory decline affecting daily life
and limiting the patient daily ability to dress and wash
themselves as well as being able to cook and eat alone. The
disease also affects language, speech and time and space
orientation and increase anxiety. Physiopathology of the
disease is characterized by b-amyloid plaques and neuroﬁbril-
lary tangles of tau protein. Together, these two components
contribute to neurodegeneration. Many pharmaceutical treat-
ments have been tried over the years but none have succeeded
to alt the progression of the disease or even treat the symptoms
of the disease. Therefore, one of the best strategies remains
prevention of the disease onset.
2 Evidence of effective prevention
strategies
Among the different prevention strategies for AD, diet has
been a lot investigated. In 2009, we have published a literature
review suggesting that consumption of ≥ 2ﬁsh servings/weeks
reduces risk of AD (Cunnane et al., 2009), Since the
publication of this paper, many other prospective and
randomized control trials (RCT) have been published and
have reported mixed results. Most of the RCT did not found a
causative effect on the consumption of ﬁsh oil. In 2013, Dacks
et al. published a review of the literature showing that in
participants without cognitive decline, taking an omega-3 fatty
acid supplement did not gain beneﬁt on cognition (Dacks
et al., 2013). In contrast, participants with subjective cognitivePage 2complaints could experience cognitive beneﬁts from taking
omega-3 fatty acid supplements (Dacks et al., 2013). A recent
study has supplemented for 2 years patients with precursor
signs of Alzheimer’s disease. The active ingredient was
composed of omega-3 fatty acids, uridine, choline, phosphates
and B vitamins but this supplementation had no effect on
cognitive scores compared to the placebo (Soininen et al.,
2017). Thus, there is currently no consensus on the
effectiveness of a nutritional strategy to prevent or limit the
progression of cognitive decline. In the absence of an effective
therapy for the treatment of Alzheimer’s disease, there is a
need to clarify whether a nutritional intervention strategy alone
or in combination with other treatments are effective.
The new trend in the ﬁeld of Alzheimer’s disease prevention
is multimodal interventions. The Finnish Geriatric Intervention
Study to Prevent Impairment and Disability (FINGER) is a
multimodal intervention that consists of a dietarymodiﬁcation to
reach the targets of nutritional recommendations of Finland,
aerobic exercise 2–5 times aweek andmuscle training 1–3 times
a week, cognitive training with group sessions to explain age-
related cognition changes, and computer-based exercises to
perform at home. This intervention also focuses on the
management of cardiovascular risks for those aged between
60 and 77 years (Ngandu et al., 2015). After 2 years of
intervention, the executive functions and the execution speed
were signiﬁcantly higher in the group that received the
intervention than in the control group, which supports that the
intervention prevented cognitive decline (Ngandu et al., 2015).
Another ongoing study in France is theMultidomain Alzheimer
Preventive Trial (MAPTstudy)which includes supplementation
with omega-3 fatty acids, as well as nutritional counselling,
physical exercise and cognitive stimulation. This procedure was
performed for 3 years in frail patients aged 70 and over. In this
study, multi-domain intervention and supplementation with
omega-3 fatty acids, alone or in combination, did not prevent
cognitive decline (Andrieu et al., 2017). Thus, multimodal
approaches should be targeted to younger people without
apparent risk factors for AD.3 Dysregulation of the metabolism of long
chain fatty acid during aging
Unlike saturated and mono-unsaturated fatty acids,
synthesis of eicosapentaenoic acid (EPA, 20:5 omega-3) and
docosahexaenoic acid (DHA, 22:6 omega-3) from its omega-3
PUFA precursor, alpha-linolenic acid (18:3 omega-3), is
extremely limited in humans (Plourde and Cunnane, 2007).









M. Plourde: OCL 2018, 25(4), D405sources such as ﬁsh and seafood. Intake of EPA and DHA from
ﬁsh normally correlates positively with the concentrations of
EPA and DHA in plasma (Vidgren et al., 1997). However,
recent data suggest that EPA levels are approximately twice
higher in plasma lipids of the elderly as compared to young
individuals, suggesting that potential alterations in EPA
incorporation and utilization occur during aging (Fortier
et al., 2010). Similar results were obtained with a DHA-
enriched supplement where the increase of DHA in plasma
total lipids was 42% higher in the elderly compared to the
young [Reviewed by (Fortier et al., 2010)]. In another study,
dietary intake of 90mg/d of DHA for 15months was not
sufﬁcient to increase DHA in plasma total lipids of both a
young elderly (aged 60–80 years old) and an old elderly (over
80 years old) group, but 180mg/d of EPA increased the plasma
EPA concentration by 53–109% (Rodriguez-Palmero et al.,
1997). Moreover, a persistent signiﬁcant positive correlation
between EPA or DHA and age even after correction for ﬁsh
intake was reported (de Groot et al., 2009), but age apparently
contributed from only 2–4% to the amount of explained
variance in EPA and DHA incorporation into plasma PL (de
Groot et al., 2009). Whether this percentage is clinically and
physiologically relevant is unknown, but it gives important
indications that incorporation of EPA and DHA is altered
during aging and as a consequence, it has the potential to alter
the utilization and uptake of these fatty acids by tissues and
organs which might enhance the risk of chronic diseases such
as cardiovascular diseases and cognitive declines. Indeed,
there are evidences supporting that higher omega-3 PUFA
levels in the erythrocyte is associated with better cognitive
functions later life (Schaefer et al., 2006) and cardiac beneﬁts
(Harris et al., 2008). Therefore, better knowledge of the
biology of aging and more speciﬁcally with regards to omega-3
PUFA metabolism would help deﬁne better nutritional
strategies for preventing diseases in the elderly.
Todoso, there is a need touse labelled fatty acids.These fatty
acids can be labeled on one or more carbons with deuterium or
the fatty acid can be uniformly labeled with carbon 13 instead of
carbon 12. The latter also allows to evaluate fatty acid beta-
oxidation since when it is beta-oxidized, it produces carbon 13
CO2 (
13C-CO2). The ﬁrst studies using uniformly labelled
carbon 13-labeled fatty acids were performed by the group of
Michel Lagarde (Lyon, France) when they investigated the
metabolism of 13C-DHA in young humans (Brossard et al.,
1996; Lemaitre-Delaunay et al., 1999). After receiving an oral
dose of 250–280mg in 13C-DHA, 13C enrichment peaked 2 h
post-dose in plasma TG when the tracer was given in the TG
form, but at 6 h post-dose when the tracer was esteriﬁed to
phosphatidylcholine (Brossard et al., 1996; Lemaitre-Delaunay
et al., 1999).Brossard et al.have reported a 1.4%apparent retro-
conversionof 13C-DHAto13C-docosapentaenoate (22:5omega-
3) and 13C-EPA3 daftergiving the tracer (Brossard et al., 1996).
These results showed the feasibility of tracingDHAmetabolism
in humans. However, neither the impact of aging on 13C-DHA
metabolism nor its beta-oxidation was investigated. We traced
13C-DHAmetabolisminsixyoung(mean27 yearsold)andsix
old (mean 77 years old) participants. We found that, 4 h post-
dose, in the elderly, 13C-DHAwas 4 times higher in plasma TG
and free fatty acids and beta-oxidation was 1.9 times higher
compared to the young (Plourde et al., 2011). Apparent retro-
conversion of 13C-DHA to other 13C-omega-3 PUFA wasPage 32.1 times higher 24 h and 7 d after tracer intake compared to the
young (Plourde et al., 2011). This result can be explained by the
elderly havingboth higher postprandial productions of very low-
density lipoproteins and free fatty acid response.Hence, because
DHAseems to remain transiently for longerperiodsof time in the
blood of the old vs. the young, it may thus indicate a lower
efﬁciency to remove DHA from the blood in the old vs. the
young, resulting in lower incorporationofDHAin themembrane
of cells that serve to initiate signaling pathways (Bazan, 2007).
Hence, by using 13C-DHA, we were able to show postprandial
alterations in themanagement ofDHAin the old compared to the
youngand increased theknowledgeon thebiologyof aging.This
lower efﬁciency potentially results in lower incorporation of
DHA in themembranes of different cells including immune cells
(Rees et al., 2006; Vandal et al., 2008; Plourde, 2009; Fortier
et al., 2010).
Our most recent work with tracers between old and young
men was conducted with 13C-eicosapentaenoic acid (13C-EPA)
or arachidonic acid (13C-ARA), two key fatty acids that are
precursors of anti- and pro-inﬂammatory cytokines, respec-
tively. Surprisingly, the kinetics of 13C-EPA and 13C-ARAwas
similar between young and old men (Leveille et al., 2017).
However, one intriguing result we obtained was that in old
men, synthesis of DHA from EPA started 2 h after tracer intake
whereas it was delayed to 1 d in young men (Leveille et al.,
2017). This result suggests that old adults might need more
DHA than what was actually provided in their diet compared to
the young adults. However, newly synthesized DHA
accumulates in the plasma of old men for 7 d and this might
be because it remains for a longer period in the plasma as
suggested by our previous study with 13C-DHA (Plourde
et al., 2011). Therefore, there might be a defect of cells such as
immune cells in old adults to uptake EPA and DHA resulting in
lower anti-inﬂammatory responses to insults. In the old men,
13C-EPA whole-body half-life was ∼14 days and in the
younger group it was ∼21 days (Leveille et al., 2017). This
result indicates that turn-over of EPA is ∼7 days faster in older
adults compared to younger adults. This is an intriguing result
since epidemiological studies and the results from a previous
study from our group (Plourde et al., 2009a) support that old
adults have twice as much plasma EPA, hence, one would
anticipate a lower whole-body turnover in old vs young adults.
Altogether, our group provided evidence that:o–f 6the level of plasma DHA is slightly modiﬁed by age but the
metabolism of DHA is highly modiﬁed by age: why the
two are disconnected needs further investigation;– the level of EPA in the plasma of old adults is twice that of
the young but the metabolism (kinetics) is only slightly
modiﬁed;– the level of ARA in the plasma is 25% higher in old vs
young adults but the kinetics is not modiﬁed by age;– are these plasma levels and kinetics imbalances obscure the
potential relationshipbetween plasman-3FAandcognition?4 One genetic risk factor of AD also
affecting DHA metabolism
Apolipoprotein E (ApoE) is a protein-regulating lipid
transport and metabolism (Mahley, 1988). The brain has its
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lipid transport to neurons. The APOE gene has three isoforms:
epsilon 2 (E2), epsilon 3 (E3) and epsilon 4 (E4). In humans,
homozygotes for E2 genotype suffer from hypertriglyceride-
mia and this feature has also been reported in apoE targeted
replacement mice with the humanE2 (hAPOE2) (Lane and
Farlow, 2005; Sharman et al., 2010). In humans, E4 is the most
important genetic risk of AD (Coon et al., 2007, Bertram and
Tanzi, 2009) and hAPOE4 mice have memory decline similar
to that reported in humans (Bour et al., 2008; Siegel et al.,
2010). Therefore, this mouse model seems to be excellent to
study APOE genotype imbalances on the metabolism of lipids.
Approximately, 20% of Canadians carry the E4 allele
which almost doubles their risk of late-onset AD whereas in
USA, the frequency of the E4 allele is around 15% (Bullido
et al., 1998). AD risk is closely linked to changes in lipid
metabolism and plasma DHA levels were inversely associated
to the brain Ab load (Yassine et al., 2016). Some suggest that
the E4 allele induce a decrease in levels of apoE protein in the
brain (i.e. loss of function) (Poirier, 2008) whereas other series
of data support a gain-of-negative function in neurite
sprouting, or any E4-speciﬁc activity in the brain (Teter,
2004). One consensus however, is related to the key role of
apoE protein in the transport and delivery of lipids within the
brain (Poirier, 2008; Poirier et al., 2014). Carrying an E4 allele
is associated with several hallmarks of AD such as Ab peptide
deposition, oxidative stress, inﬂammation, lipid homeostasis
deregulation, loss of synaptic plasticity and cholinergic
dysfunction (Mahley et al., 2009; Kim et al., 2014; Poirier
et al., 2014; Salem et al., 2015).
The story about carrying the E4 allele and DHA
metabolism imbalance emerge when a paper was published
in 2005 by Huang et al. (2005). This group showed that
beneﬁts of fatty ﬁsh on dementia risks were stronger for those
without the E4 allele. Our group proposed that this lack of
beneﬁt was potentially because of DHA imbalance. We then
tested whether E4 carriers were responders to an EPAþDHA
supplement. This was performed as a pilot study in a secondary
analysis of a study originally designed by Prof Vohl (Paradis
et al., 2005). We compared the fatty acid proﬁle of the
different lipid pools in the plasma: phospholipids, free fatty
acids, triglycerides (TG) and cholesteryl esters. Before the
EPAþDHA supplementation, the level of DHA in plasma TG
was 55% higher in E4 carriers compared to non-carriers
(Plourde et al., 2009b). After consuming 1.8 g/d EPAþ 1.2 g/d
DHA for 6weeks, DHA increased by 65% in plasma TG of E4
carriers while the increase was by 180% in the non-carriers
(Plourde et al., 2009b). We then conducted a study using 13C-
DHA in E4 carriers and non-carriers and we found that its
kinetics was imbalanced in E4 carriers in the postprandial
phase (Chouinard-Watkins et al., 2013). Ones could question
how important these imbalances play to better health. It is
important to know that the plasma DHA pool is critical to bring
DHA to the brain and it is dynamic, constantly exchanging FA
with organs and tissues. Under conditions of chronic low
dietary n-3 FA, the liver usually upregulates its ability to
synthesize DHA and presumably receives alpha-linolenic acid
(ALA) from the adipose tissue. Hence, it is suggested that there
is an adipose-liver-brain FA axis (Bazinet and Laye, 2014). In
mice, we recently published that under an omega-3 FA
deﬁcient diet, hAPOE4mice had similar plasma DHA levels toPage 4that of hAPOE3mice, but the liver and the adipose tissue DHA
levels were ∼46% lower in hAPOE4 mice than in hAPOE3
mice fed the same diet (Nock et al., 2017). Therefore, to
maintain plasma DHA levels, hAPOE4 mice had to pull DHA
from, or prevent DHA getting into the liver and the adipose
tissue. The reasons for maintaining plasma DHA levels might
be to support brain DHA levels as we have shown that
consequences on brain FA proﬁle of hAPOE4mice consuming
a deprived diet in omega-3 FA are only expressed in the long
term since the ALA and DHA reservoir gets empty (Conway
et al., 2014; Vandal et al., 2014). This condition accentuates
their vulnerability to omega-3 FA deﬁciency. The ALA:
linoleic acid (LA) ratio, an indicator of the capacity to convert
ALA to DHA was ∼80% lower in the liver of hAPOE4
compared to hAPOE3 mice. We recently reviewed the
neurological consequences of omega-3 FA dietary deﬁciency
that includes a 3-fold reduction in the capillaries of the adult rat
brain, smaller neuron size and lower neuronal membrane
ﬂuidity (Nock et al., 2017). Hence, hAPOE4 might be more
vulnerable to omega-3 FA deﬁciency and this process might be
accentuated during aging due to a loss of delta-6 desaturase
activity as expressed by the ALA: LA ratio (Horrobin, 1981).
Another important point with regards to brain DHA uptake
is that, in mice, it was shown to be not saturable at
concentrations up to 100microM suggesting that it crosses
the blood-brain barrier (BBB) by simple diffusion. We showed
in hAPOE4 mice, that brain 14C-DHA uptake was 24% lower
in hAPOE4 than hAPOE2 mice but cortex DHA levels were
lower in 13month-old hAPOE4 mice only (Vandal et al.,
2014). Abdullah et al. suggested that Mfsd2a level, a brain
transport protein of lyso-phosphatidylcholine-DHA (lyso-PC-
DHA), was lower in E4 carriers and in hAPOE4 mice
compared to that of E3 carriers and hAPOE3 mice (Abdullah
et al., 2016). Lower Mfsd2a levels correlated with lower DHA
and a higher ARA levels in brain membrane (Abdullah et al.,
2016). Her group also showed that E4 carriers converting to
mild cognitive impairment (MCI)/AD had higher ARA: DHA
ratio in PC and lyso-PC compared to cognitively normal E4
carriers and E4 non-carriers (Abdullah et al., 2017). Aldullah
et al. also reported a similar higher ARA: DHA ratio in PC and
lyso-PC in hAPOE4 mice compared to hAPOE3 mice
supporting that this mice model also have an imbalance in
DHA and ARA compartment packaging (Abdullah et al.,
2017). In ∼35 year-old humans, a positron emission tomogra-
phy study with [1-11C]-DHA reported however, that the mean
global gray matter incorporation of DHA in the brain of E4
carriers was 16% higher than in non-carriers (Yassine et al.,
2017). This higher uptake was particularly emphasized in the
entorhinal region, an area affected early in AD pathogenesis
and it was suggested by the authors it might represent a
compensatory mechanism in younger E4 carriers to cope with
increased brain DHA loss thus to maintain brain DHA levels
(Yassine et al., 2017). Therefore, at younger ages, E4 carriers
might require more DHA than non-carriers to support brain
DHA turnover and prevent accumulation of Ab peptide since it
was shown that higher plasma DHA levels were inversely
associated to the brain Ab load (Yassine et al., 2016). However,
Abdullah et al. showed that a ﬁsh oil supplement modulate the
ARA: DHA ratio in carriers and non-carriers of E4 suggesting
that E4 carrier could somehow beneﬁt from a ﬁsh oil









M. Plourde: OCL 2018, 25(4), D405be conditional to higher doses and longer duration than what
has currently been published yet on the topic. This hypothesis
is supported by our recent study in hAPOE4mice fed a control
or a diet containing DHA where the DHA diet in hAPOE4
prevented spatial memory deﬁcits as compared to the control
diet (Chouinard-Watkins et al., 2017). However, the
mechanism explaining this preventive effect remains unknown
(Chouinard-Watkins et al., 2017). In another study, the authors
reported that the metabolic and cognitive deﬁcits in hAPOE4
mice fed a high fat diet inducing insulin resistance were
rescued by switching to a low fat diet for 1month suggesting a
functional role of dietary FA in hAPOE4 mice on top of a
structural role (Johnson et al., 2017). Therefore, it seems that
hAPOE4 mice could beneﬁt from a higher consumption in
DHA (Chouinard-Watkins et al., 2017) but this remains to be
established in humans. A recent paper from the FINGER study,
a multidomain intervention of 2 years, support this hypothesis
since they concluded that healthy lifestyle changes may sustain
cognition in older at-risk E4 carriers (Solomon et al., 2018).
Although it do not related speciﬁcally to omega-3 fatty acid
metabolism/supplementation, it indicates that AD risk can be
modulated in E4 carriers and non-carriers and thus, this
strategy should be encourage and developed better to be
implemented in our communities.
5 Conclusion
There is currently no cure nor treatment to AD. Prevention
strategies are urgently needed since the aging population will
be one of the most signiﬁcant forces shaping our economy and
society in the next 20–30 years. Moreover, there is 15–20% of
the population carrying the E4 genetic risk that increases the
risk of AD. However, not all E4 carriers develop AD
suggesting that lifestyle such as nutrition can modulate AD
expression. We have identiﬁed that DHA metabolism is
imbalanced during aging and in E4 carriers and these
imbalances could limit DHA delivery to replenish brain
DHA levels during aging and in E4 carriers. Our work
contributes to understand how to limit these defects and help to
decrease the risk of AD in E4 carriers. A reduction of even
10% in the prevalence of AD would markedly diminish the
impact of this disease on society and on life quality of the aging
population.
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